APEIRON Biologics Receives Green Light for Marketing Approval of a Neuroblastoma Immunotherapy in the European … – PR Newswire (press release)
|
APEIRON Biologics Receives Green Light for Marketing Approval of a Neuroblastoma Immunotherapy in the European …
PR Newswire (press release) Dr. Hans Loibner, Apeiron's Chief Executive Officer, said, "We are delighted with the CHMP positive opinion for approval of dinutuximab beta for immunotherapy of high risk neuroblastoma, an area of significant unmet medical need. We regard this as key … |
